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NVA237 is a novel, once daily inhaled long-acting muscarinic antagonist administered via a dry
powder inhaler. This study aimed to assess the 24-h bronchodilatory effect following 14 days of
treatment with inhaled NVA237 in patients with mild, moderate or severe COPD.
This was a randomized, double-blind, placebo-controlled, two-period, crossover, multi-
center study. A total of 33 patients (40 years; smoking history of 10 pack-years) were
randomized to receive NVA237 50 mg once daily followed by placebo or placebo followed by
NVA237 50 mg for 14 days. Treatment periods were separated by a 7e14 day washout period.
The primary variable was the mean forced expiratory volume in 1 s (FEV1) derived from the
area under the curve (AUC) between 0 and 24 h post-dose on Day 14.
The 24-h FEV1 profiles showed a consistent bronchodilator effect for NVA237 versus placebo
on Day 14. Least square (LS) mean difference in FEV1 AUC0e24 h values between NVA237 and
placebo was 163 mL (P < 0.001). There were significant increases in mean FEV1 AUC0e12 h
(LS mean difference 165 mL, P Z 0.001) and FEV1 AUC12e24 h (161 mL, P < 0.001) versus
placebo. NVA237 significantly improved peak FEV1 (by 208 mL, P < 0.001) and trough FEV1
(by 154 mL, P Z 0.003) versus placebo on Day 14. NVA237 was well tolerated; all adverse
events were mild or moderate in intensity and not related to study drug.
NVA237 50 mg once daily was well tolerated and showed significant and sustained 24-h
bronchodilation in patients with COPD.
ª 2010 Elsevier Ltd. All rights reserved.1 324 2548; fax: þ41 61 324
novartis.com (A. Drollmann).
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Chronic obstructive pulmonary disease (COPD) is a leading
cause of morbidity and mortality worldwide. It is charac-
terized by progressive airflow limitation that is not fully.
d Breezhaler is a registered trademark of Novartis Pharma AG,
Basel, Switzerland.
338 C. Fogarty et al.reversible in most patients. Guidelines have recognized
that COPD is both preventable and treatable; however, it is
frequently under-diagnosed and under-treated in clinical
practice.1,2
Management of COPD requires individualized therapy to
prevent and control symptoms, reduce the frequency and
severity of exacerbations, and to improve exercise tolerance
and quality of life.1 Treatment with bronchodilators is
essential to the symptomaticmanagement of COPD.1 Inhaled
muscarinic antagonists, such as ipratropium and tiotropium
bromide, are one of themain classes of bronchodilators used
for the treatment of COPD. Short-acting ipratropium3,4 and
long-acting tiotropium5,6have been shown to improve lung
function and reduce COPD symptoms. Both agents are
generally well tolerated in patients with COPD.1
NVA237 is a novel inhaled dry powder formulation of the
long-acting muscarinic antagonist glycopyrronium bromide.
It is currently in development as a once daily bronchodilator
for the treatment of COPD. Preclinical studies demonstrated
that NVA237 has both high affinity for and slow dissociation
from muscarinic receptors; an optimal profile for prolonged
bronchodilation.7 NVA237 has a fast onset of effect and
provides sustained 24-h bronchodilation. The safety and
efficacy of NVA237 has been demonstrated studies in patients
withmoderate-to-severeCOPD.8,9NVA237 iswell toleratedat
doses of up to200mg in this patient population.9 The results of
a recent dose-ranging study indicate that 50 mg NVA237
provides bronchodilation that is both statistically significant
and clinically relevant (pre-defined threshold exceeded, i.e.
>120 mL). The magnitude of bronchodilation observed with
50 mg NVA237 is similar to that observed with open-label tio-
tropium 18 mg (131 mL versus 127 mL, respectively).8
While previous studies have shown that NVA237 has a fast
onset of effect that is sustained over 24 h,8,9 a comprehen-
sive 24-h bronchodilator profile of NVA237 has not been
characterized to date. The present study in patients with
mild,moderate or severe stable COPDwas designed to assess
the bronchodilatory effect of 50 mg NVA237 inhaled once
daily compared with placebo, over the 24-h interval
following 14 day’s treatment.
Methods
Patients
Eligible patients were aged 40 years with stable mild,
moderate or severe COPD according to the 2008 GOLD
guidelines,10 and a smoking history of at least 10 pack-years.
Patients were required to have post-bronchodilator forced
expiratory volume in 1 s (FEV1) 30% of the predicted
normal value and post-bronchodilator FEV1/forced vital
capacity (FVC) of<0.7 at Visit 1; FEV1 must increase by 5% or
more following inhalation of ipratropium bromide in the
bronchial reversibility test.
Patients were excluded if they required oxygen therapy
onadaily basis for chronic hypoxemia, hada respiratory tract
infection within 6 weeks prior to screening, or had been
hospitalized for an exacerbation of airways disease in the
6 weeks before screening or during the screening period.
Other exclusion criteria included: a history of asthma; pro-
longed heart-rate correctedQT interval (QTc) at screening ora history of QT syndrome; an untoward reaction to anti-
cholinergics or contraindications for antimuscarinic agents;
pregnancy or lactation; any other clinically relevant labo-
ratory abnormality or clinically significant condition that
might have compromised patient safety or compliance.
Medications for the treatment of COPD or allied condi-
tions were not permitted during the study and were to be
discontinued for an appropriate period prior to study
screening. Patients requiring inhaled corticosteroids,
cromoglycate, ketotifen or nedocromil had to be using
a stable dose for at least one month prior to first study
treatment. Patients were not enrolled if they were unable
to use the Breezhalerd device, a single-dose dry powder
inhaler (SDDPI), a pMDI (rescue medication) or perform
spirometry measurements; were receiving b-blocking
agents that were not highly b1 receptor-selective; or had
received an investigational drug within 30 days or five half-
lives prior to enrolment or dose administration. Women of
child-bearing potential were excluded unless they were
using appropriate contraception.
Study design
This was a randomized, double-blind, placebo-controlled,
two-period, crossover, multicenter trial (ClinicalTrials.gov
identifier: NCT00856193) with a treatment duration of 14
days per period. The study consisted of a screening period
(performed between 21 and 2 days prior to first dose) and the
two treatment periods separated by awashout phase of 7e14
days. Study medication was administered via the
Breezhaler device, a low-resistance SDDPI suitable for use
by a wide range of patients with COPD.11 A study completion
evaluation was performed on Day 15 of Period 2.
This study was conducted according to the ethical princi-
ples of the Declaration ofHelsinki. The protocolwas reviewed
by the Independent Ethics Committee or Institutional Review
Board for each participating centre. All patients provided
written informed consent before enrolling in the study.
Study assessments and variables
Efficacy measurements were carried out on Day 1 (at 45 and
15 min pre-dose and at 5, 15 and 30 min and 1, 2, 3, 4 and
5 h post-dose), Day 7 (at 45 and 15 min pre-dose and at 5,
15 and 30 min and 1, 2, 3, 4, 5, 6, 10, 11.75, 23.25 and
23.75 h post-dose) and Day 14 (at 45 and 15 min pre-dose
and at 5, 15 and 30 min and 1, 2, 3, 4, 5, 6, 10, 11.75, 13,
14, 20, 22, 23.25 and 23.75 h post-dose).
The primary efficacy variable was the standardized FEV1
area under the curve (AUC) between 0 and 24 h post-dose on
Day 14. Secondary efficacy variables included AUC0e5 h,
AUC0e12 h and AUC12e24 h for FEV1 on Day 14 (12 h was defined
as the 11 h 45 min assessment), peak (defined as the highest
value in the response profile on Day 1, 7 and 14, respectively)
and trough FEV1 (defined as the mean of the 23 h 15 min and
23 h 45 min post-dose assessments), the standardized FEV1
AUC0e5 h on Day 1 and AUC0e12 h on Day 7. The home moni-
toring device (Pikometer) for FEV1 was used as a validation
Figure 1 Patient disposition (safety population).
Table 1 Patient baseline demographics and clinical
characteristics (safety population).
Total
(n Z 33)
Age (years), mean (SD) 60.5 (9.1)
Range 46e81
Sex, n (%)
Male 22 (66.7)
Race, n (%)
Caucasian 31 (93.9)
Black 2 (6.1)
Duration of COPD (years),
mean (SD)
4.8 (3.8)
FEV1 (L) pre-bronchodilator,
mean (SD)a
1.8 (0.8)
FEV1 (L) post-bronchodilator,
mean (SD)a
2.1 (0.8)
FEV1 % predicted pre-bronchodilator,
mean (SD)a
58.9 (21.1)
FEV1 % predicted post-bronchodilator,
mean (SD)a
69.7 (21.1)
FEV1 reversibility (%),
mean (SD)
21.8 (16.0)
FVC (L) pre-bronchodilator,
mean (SD)a
3.3 (1.2)
FVC (L) post-bronchodilator,
mean (SD)a
3.7 (1.3)
FEV1/FVC (%) pre-bronchodilator,
mean (SD)a
54.0 (10.0)
FEV1/FVC (%) post-bronchodilator,
mean (SD)a
56.7 (10.6)
SD Z standard deviation; COPD Z chronic obstructive pulmo-
nary disease; FEV1 Z forced expiratory volume in 1 s;
FVC Z forced vital capacity.
a Ipratropium bromide.
Bronchodilatory effects of NVA237 in COPD patients 339test in this study. Profiles performed at home (Day 13) and
while in the clinic (Day 14) were compared descriptively
between treatment days (Day 13 versus Day 14) and with the
‘standard’ spirometry assessments (Pikometer versus
spirometry) on Day 14.
Safety assessments included the incidence of all adverse
events (AEs), serious adverse events (SAEs), with their
severity and relationship to the study drug. In addition,
changes in blood chemistry and hematologyweremonitored,
and vital signs, physical condition and electrocardiograms
(ECG) were regularly assessed throughout the study.
Statistical analyses
The crossover design of this study allowed the total
number of patients analyzed to be kept to a minimum. A
sample size of 26 patients was estimated to provide about
90% power to detect a clinically significant increase of
120 mL in standardized AUC0e24 h for FEV1 (24 h was
defined as the 23 h 45 min assessment), assuming a two-
sided significance level of 0.05 and standard deviation
(SD) of 180 mL for within-patient differences. Originally,
32 patients were to be randomized to ensure approxi-
mately 26 completers.
All patients who completed at least one treatment
period were included in the efficacy analysis. The primary
efficacy analysis variable was standardized FEV1 AUC024 h,
following 14 days of treatment; the linear trapezoidal rule
was used to calculate the AUC. Standardized FEV1
AUC024 h was analyzed with an analysis-of-covariance
(ANCOVA) model, which included: treatment sequence,
treatment and period as fixed factors, baseline FEV1 value
as a covariate and patient as a random effect. The least
square (LS) mean difference (with 95% confidence inter-
vals) between NVA237 and placebo was estimated. Baseline
was defined as the mean of the 45 and 15 min pre-dose
values on Day 1 of each treatment period. Secondary effi-
cacy variables were analyzed in a similar manner to the
primary variable.
Safety assessments were conducted in the safety pop-
ulation, which included all patients who received at least
one dose of study medication. Safety variables are summa-
rized descriptively.
Results
Disposition and baseline characteristics
A total of 33 patients were enrolled into this study (Fig. 1).
Two patients were withdrawn, one for abnormal test
procedure results and one who was lost to follow-up. The
majority of patients were male (66.7%) and Caucasian
(93.9%). Other baseline demographic and clinical charac-
teristics are shown in Table 1.
Efficacy
Primary efficacy variable
FEV1 AUC0e24 h values on Day 14were significantly (P< 0.001)
higher for NVA237 than for placebo; LS mean difference of163 mL between NVA237 and placebo. Mean 24-h profiles of
FEV1 on Day 14 (efficacy analysis set) are presented in Fig. 2.
Secondary efficacy variables
A summary of the statistical analysis of FEV1 AUC values
assessedas secondary efficacy variables is provided inTable2.
FEV1 with NVA237 was significantly higher (P < 0.001) than
placebo for all AUCs evaluated. On Day 14, there were
significant increases in mean FEV1 AUC05 h (difference
198 mL, P < 0.001), FEV1 AUC012 h (difference 165 mL,
P Z 0.001) and FEV1 AUC1224 h (161 mL, P < 0.001) versus
Figure 2 Twenty-four-hour bronchodilatory effect on Day 14 (efficacy analysis set).* FEV1 Z forced expiratory volume in 1 s;
AUC Z area under the curve. Values are expressed as mean  standard error. *Only patients with FEV1 values in both periods for
a given time point were included.
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onDay 7 by 185mL (P< 0.001) andmean FEV1 AUC05 h on Day
1 by 172 mL (P < 0.001) versus placebo.
All primary analyses for trough FEV1 comparisons showed
a clinically significant effect (pre-defined threshold
exceeded, i.e. >120 mL) at the 5% confidence level, except
for the treatment LS mean difference in trough value for
NVA237 on Day 7 (91 mL; 95% CI 0.011, 0.192). The
difference in trough values between NVA237 and placebo
on Day 14 was 154 mL (P Z 0.003). A clinically significant
effect was reported for all peak FEV1 comparisons. The
mean difference in peak values between NVA237 and
placebo was 208 mL (P < 0.001) on Day 14 and 173 mL
(P Z 0.011) on Day 7.
Safety
NVA237 was well tolerated. In total, five (15%) of the 33
patients experienced at least one AE (Table 3); three of
these patients experienced an event only with placebo, one
patient only with NVA237 and the fifth patient with both
NVA237 and placebo Almost all AEs observed in the study
were of mild intensity; one AE of moderate intensity was
reported: toothache (in the placebo group). No SAEs orTable 2 Statistical analysis of the FEV1 AUC values assessed a
model).
Parameter Day Treatment n LS mea
AUC0e5 h 1 Placebo 33 1.849
NVA237 31 2.021
14 Placebo 32 1.744
NVA237 31 1.942
AUC0e12 h 7 Placebo 28 1.806
NVA237 31 1.991
14 Placebo 32 1.714
NVA237 31 1.879
AUC12e24 h 14 Placebo 32 1.615
NVA237 31 1.776
FEV1 Z forced expiratory volume in 1 s; AUC Z area under curve; LS
a adjusted for baseline covariate.severe events were reported. All AEs were transient in
nature and not thought to be related to the study drug.
There were no clinically relevant changes in hematological
or biochemical measures during the study. In addition, there
were no clinically relevant changes in vital signs or ECGs.
Discussion
The results of this study indicate that 50 mg NVA237 has
a fast onset of effect, with a significant and sustained
bronchodilatory effect over 24 h compared with placebo.
NVA237 significantly improved pulmonary function in
patients with mild, moderate or severe stable COPD. The
bronchodilatory effect was sustained for 24 h following 14
days of once daily treatment, as evidenced by significantly
higher FEV1AUC024 h values versus placebo (primaryefficacy
variable). The mean difference in FEV1 AUC024 h values
betweenNVA237 andplacebowas 163mL (P< 0.001). Results
obtained for secondary variables also showed that the effi-
cacy of NVA237 was sustained over the full 24-h dosing
interval, as indicated by the similar bronchodilatory
response over the first (0e12 h) and second (12e24 h) frac-
tion of the dosing interval. The bronchodilator effect of
NVA237 once daily appears to be sustained for at least as longs secondary efficacy variables (efficacy analysis set, ANCOVA
n SE Contrast to placebo LS
mean (95% CI)a
P value
0.0235
0.0242 0.172 (0.116, 0.228) <0.001
0.0340
0.0346 0.198 (0.102, 0.294) <0.001
0.343
0.0325 0.185 (0.088, 0.282) <0.001
0.0340
0.0346 0.165 (0.073, 0.257) 0.001
0.0339
0.0344 0.161 (0.079, 0.234) <0.001
Z least square; SE Z standard error; CI Z confidence interval.
Table 3 All adverse events reported in the safety pop-
ulation (n, %).
Adverse event NVA237 50 mg
(n Z 31)
Placebo
(n Z 33)
Total 2 (7) 4 (12)
Abdominal discomfort 1 (3) 0
Periodontitis 0 1 (3)
Toothache 0 1 (3)
Gastroenteritis viral 0 1 (3)
Dysphonia 0 1 (3)
Pruritus 1 (3) 0
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tropium 18 mg once daily for 6 weeks increased mean FEV1
AUC by 127 mL from baseline during the first 12 h post-dose,
and by 43 mL 12e24 h post-dose. In comparison with ipra-
tropium bromide, the bronchodilator effect of NVA237 once
daily is sustained for longer; ipratropium bromide has a 6 h
duration of action, thereby necessitating four times daily
administration to maintain efficacy over 24 h13
While the results of this study clearly demonstrate that
NVA237 provides significant sustained 24-h bronchodilation,
moderatefluctuations in the effects ofNVA237 versus placebo
on Day 14 are apparent within the dosing interval. These
fluctuations may be caused by the methodological variability
of spirometry. Physiological fluctuations of bronchomotor
tone, and thus expiratory flow, over the day could also have
influenced the results; activity of the sympathetic system is
postulated to be more prominent in the day, whereas para-
sympathetic systemactivity is increasedduring thenight.14e16
Previously it has been postulated that receptor binding
kinetics, in combination with in vivomodels in dogs, may be
predictive of the differences in duration of action of inhaled
antimuscarinic compounds.17 In these settings there were
differences in the receptor dissolution and duration of
action between tiotropium and NVA237. The missing link to
the observations in clinical studies may be related to the
fact that receptor binding kinetics are only one fractional
part of compound pharmacology and can therefore not
reliably predict the duration of action of a compound
administered to the lung. Experimental in vitro settings
should try to better approximate physiological conditions
and utilise formulations that are representative of those
used in the clinic. Clinical data of NVA237 show similar
response profiles compared with tiotropium up to 24 h after
dosing. The dose response pattern of NVA237 appeared to be
in the same dose order early after dosing as well at 24 h
after dosing, making it unlikely that the 24 h duration of
action is achieved by using an unnecessarily high dose.8 The
clinical data presented in this paper shows that NVA237 is
effective 24 h post-dose and confirm the results of previous
studies in patients with COPD.8,9
NVA237 improved all other FEV1 AUC values analyzed
compared with placebo. On Day 14, mean FEV1 AUC0e5 h
increased by 198 mL (P < 0.001). In addition, mean FEV1
AUC0e5 h on Day 1 increased by 172mL (P< 0.001). This result
provides further evidence that NVA237 has a fast onset of
effect, and suggests that patientsmay experience rapid relief
from symptoms of dyspnea after starting treatment. Peak and
trough FEV1 were assessed on Day 7 and Day 14 of the study.Treatment with NVA237 was associated with a consistent,
statistically significant effect versus placebo on peak FEV1
values on both days. Trough values on Day 14 were also
significantly greater in NVA237-treated patients. The effect
on trough FEV1 values was in the range of that observed with
the clinical use of tiotropium and ipratropium bromide.6,13,18
Overall, the results of this study are consistent with
previous findings that once daily NVA237 provides sustained
24-h bronchodilation with a fast onset of effect.8,9
NVA237 was well tolerated. Only two patients experienced
AEs while receiving NVA237; all were mild and not related to
the study drug. In addition, local anti-cholinergic side effects,
such as dry mouth which has been reported in 15e16% of
patients taking tiotropium,5,6werenot observed in thepresent
study. Thismight bedue to the short treatmentduration of this
study, as a median time of onset of dry mouth of 4 weeks has
previously been reported with ipratropium and tiotropium.5
Overall, the safety results are consistent with previous find-
ings demonstrating the good safety profile of NVA237.8,9
In summary, compared with placebo, NVA237 50 mg
showed significant and sustained bronchodilatory efficacy
in patients with mild, moderate or severe COPD, and was
well tolerated. The results of the present study provide
additional evidence to support the continued development
of once daily NVA237 for the treatment of COPD.Acknowledgements
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